Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00541112
Other study ID # CDR0000565937
Secondary ID FRE-FNCLCC-ACCOR
Status Terminated
Phase Phase 2
First received
Last updated
Start date October 29, 2007
Est. completion date January 29, 2010

Study information

Verified date February 2020
Source UNICANCER
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving radiation therapy together with combination chemotherapy and cetuximab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy and cetuximab after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II clinical trial is studying how well giving radiation therapy together with chemotherapy and cetuximab followed by surgery, chemotherapy, and cetuximab works in treating patients with locally advanced or metastatic rectal cancer that can be removed by surgery.


Description:

OBJECTIVES:

Primary

- Determine the complete remission rate at 6 months after neoadjuvant radiotherapy, capecitabine, and oxaliplatin (XELOX), and cetuximab followed by surgery, adjuvant FOLFOX 4, and cetuximab in patients with synchronous locally advanced or metastatic cancer of the rectum with resectable metastases (T3-4 Nx or T2 N+ M1).

Secondary

- Determine progression-free survival.

- Determine overall survival.

- Assess toxicities.

- Evaluate objective response in patients with measurable metastases.

- Determine the rate of local recurrence.

- Evaluate the downstaging and downsizing of patients with operable disease.

- Evaluate surgical complications in patients with operable disease.

- Evaluate biological markers predictive of response to cetuximab.

OUTLINE: This is a multicenter study.

- Neoadjuvant therapy: Patients undergo radiotherapy for 5 weeks and receive concurrent oral capecitabine twice daily on days 1-5 of each week and oxaliplatin IV over 2 hours on day 1 of each week (XELOX). Patients also receive cetuximab IV on day 1 of the first week and on days 1-7 of weeks 2-5.

- Surgery: At 6 weeks after completing chemoradiotherapy, patients with resectable disease undergo surgery comprising total mesorectal excision. Patients with progressive disease, nonresectable tumor, or who require R2 surgery are removed from the study.

- Adjuvant therapy: Patients who undergo surgery, with or without removal of metastases, receive FOLFOX 4, comprising oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours, and leucovorin calcium IV on day 1, and cetuximab IV. Treatment repeats every 2 weeks for up to 6 courses (approximately 3 months). Patients who have not undergone prior surgical resection of metastases may have surgery to remove metastases after completing this second regimen of chemotherapy.

After completion of study therapy, patients are followed periodically for up to 5 years.


Recruitment information / eligibility

Status Terminated
Enrollment 19
Est. completion date January 29, 2010
Est. primary completion date January 29, 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed adenocarcinoma of the rectum

- Locally advanced (T3-4 Nx) or metastatic (T2 N+ M1) synchronous disease

- Metastases must be resectable

- Primary tumor examined by endorectal echography and MRI

- Measurable disease by thoraco-abdomino-pelvic scanner

- Disease considered susceptible to treatment with radiotherapy and chemotherapy

- No diffuse metastases considered nonresectable

- No acute occlusion not caused by colostomy

PATIENT CHARACTERISTICS:

Inclusion criteria:

- ECOG performance status 0-2

- WBC = 4,000/mm^3

- Absolute neutrophil count = 1,500/mm^3

- Platelet count = 100,000/mm^3

- Hemoglobin = 10 g/dL

- Creatinine = 130 µmol/L

- Transaminases = 5 times upper limit of normal (ULN)

- Total bilirubin = 1.5 times ULN

- Alkaline phosphatase = 2.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients of must use effective contraception

Exclusion criteria:

- Contraindication to therapy with capecitabine, oxaliplatin, cetuximab, and/or radiotherapy

- Impossible to perform translational analyses

- Uncontrolled severe illness

- Severe renal or hepatic insufficiency

- Cardiac insufficiency or symptomatic coronary disease

- Sensitive peripheral neuropathy

- Uncontrolled diabetes

- Other malignancy within the past 10 years except previously treated basal cell skin cancer or carcinoma in situ of the cervix

- Impossible to participate in study due to geographic, social, or psychiatric reasons

- Patients who are under supervision or incarcerated

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior anticancer chemotherapy or radiotherapy for this cancer

- No therapy with coumarin anticoagulants, phenytoin, sorivudine, brivudine, antacids, or allopurinol

- No concurrent participation in another therapeutic study or receiving another experimental drug

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
cetuximab

Drug:
capecitabine

fluorouracil

leucovorin calcium

oxaliplatin

Procedure:
adjuvant therapy

conventional surgery

neoadjuvant therapy

Radiation:
radiation therapy


Locations

Country Name City State
France Institut Bergonie Bordeaux
France Centre de Lutte Contre le Cancer Georges-Francois Leclerc Dijon
France Centre Oscar Lambret Lille
France Centre Leon Berard Lyon
France Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle Montpellier
France Centre Antoine Lacassagne Nice
France Centre Hospitalier Lyon Sud Pierre Benite
France Centre Rene Huguenin Saint Cloud
France Centre Alexis Vautrin Vandoeuvre-les-Nancy
France Institut Gustave Roussy Villejuif

Sponsors (1)

Lead Sponsor Collaborator
UNICANCER

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete remission at = 6 months by abdomino-pelvic-thoracic scan and a pelvic MRI
Secondary Preoperative clinical response
Secondary Progression-free survival
Secondary Overall survival
Secondary Early toxicity before surgery
Secondary Early toxicity due to surgery (mortality at 30 days, postoperative complications, surgical recovery)
Secondary Late toxicity
Secondary Late radiotherapy toxicity by CTC AE v. 3.0
Secondary Objective response of measurable metastases by RECIST
Secondary Sexual function
Secondary Downstaging and downsizing of patients with operable disease
Secondary Surgical complications
Secondary Sphincter function
Secondary Predictive biomarkers of response to cetuximab
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A